Proteomics in clinical chemistry: Will it be long?

Trends in Biotechnology

Volumn 28, Issue 5, 2010, Pages 225-229

  Lescuyer, Pierre ^a,b   Farina, Annarita ^b   Hochstrasser, Denis F ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL CHEMISTRY; CLINICAL PRACTICES; HUMAN DISEASE; LABORATORY MEDICINES; MEDICAL LABORATORIES; PROTEIN ANALYSIS; PROTEOMICS; QUALITY OF RESULTS; SHORT TERM;

BIOCHEMISTRY; CLINICAL LABORATORIES; DIAGNOSIS; MOLECULAR BIOLOGY; PROTEINS;

CHEMICAL LABORATORIES;

ANALYTIC METHOD; ARTICLE; CAPILLARY ELECTROPHORESIS MASS SPECTROMETRY; CLINICAL CHEMISTRY; CLINICAL LABORATORY; INFORMATION PROCESSING; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; QUALITY CONTROL; REACTION ANALYSIS; STANDARDIZATION; SURFACE ENHANCED LASER DESORPTION IONIZATION MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY;

ANIMALS; CHEMISTRY, CLINICAL; HUMANS; MASS SPECTROMETRY; PROTEOMICS; QUALITY CONTROL;

EID: 77951978991     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibtech.2010.02.004     Document Type: Article

References (60)

1. Choudhary C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
2. Picotti P., et al. Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics. Cell 2009, 138:795-806.
3. Xu P., et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009, 137:133-145.
4. Service R.F. Proteomics. Will biomarkers take off at last?. Science 2008, 321:1760.
5. Hanash S.M., et al. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
6. Taylor C.F., et al. Guidelines for reporting the use of mass spectrometry in proteomics. Nat. Biotechnol. 2008, 26:860-861.
7. Binz P.A., et al. Guidelines for reporting the use of mass spectrometry informatics in proteomics. Nat. Biotechnol. 2008, 26:862.
8. Gibson F., et al. Guidelines for reporting the use of gel electrophoresis in proteomics. Nat. Biotechnol. 2008, 26:863-864.
9. Tang N., et al. Current developments in SELDI affinity technology. Mass Spectrom. Rev. 2004, 23:34-44.
10. Poon T.C. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev. Proteomics 2007, 4:51-65.
11. Whelan L.C., et al. Applications of SELDI-MS technology in oncology. J. Cell Mol. Med. 2008, 12:1535-1547.
12. Hortin G.L. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 2006, 52:1223-1237.
13. Villanueva J., et al. Monitoring peptidase activities in complex proteomes by MALDI-TOF mass spectrometry. Nat. Protoc. 2009, 4:1167-1183.
14. Lay J.O. MALDI-TOF mass spectrometry of bacteria. Mass Spectrom. Rev. 2001, 20:172-194.
15. Cherkaoui, A. et al. (2010) Comparison of two matrix-assisted laser desorption Ionization-time of flight mass spectrometry methods with conventional phenotypic identification for routine identification of bacteria to the species level. J. Clin. Microbiol. (). http://jcm.asm.org/.
16. Kleparník K., Bocek P. DNA diagnostics by capillary electrophoresis. Chem. Rev. 2007, 107:5279-5317.
17. Sniehotta M., et al. CE - a multifunctional application for clinical diagnosis. Electrophoresis 2007, 28:1407-1417.
18. Tagliaro F., et al. Recent advances in the application of CE to forensic sciences: a update over years 2007-2009. Electrophoresis 2010, 31:251-259.
19. Kolch W., et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom. Rev. 2005, 24:959-977.
20. Mischak H., et al. Proteomics in uremia and renal disease. Semin. Dial. 2009, 22:409-416.
21. Caubet C., et al. Advances in urinary proteome analysis and biomarker discovery in pediatric renal disease. Pediatr. Nephrol. 2010, 25:27-35.
22. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Proteomics 2006, 5:573-588.
23. Kitteringham N.R., et al. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877:1229-1239.
24. Keshishian H., et al. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics 2007, 6:2212-2229.
25. Kuzyk M.A., et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell Proteomics 2009, 8:1860-1877.
26. Keshishian H., et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Proteomics 2009, 8:2339-2349.
27. Han B., et al. Development of a highly sensitive, high-throughput, mass spectrometry-based assay for rat procollagen type-I N-terminal propeptide (PINP) to measure bone formation activity. J. Proteome Res. 2007, 6:4218-4229.
28. Kulasingam V., et al. Product ion monitoring" assay for prostate-specific antigen in serum using a linear ion-trap. J. Proteome Res. 2008, 7:640-647.
29. Lopez M.F., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56:281-290.
30. Kumar V., et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 2010, 56:306-313.
31. Guder W.G. Preanalytical factors and their influence on analytical quality specifications. Scand. J. Clin. Lab. Invest. 1999, 59:545-549.
32. Baumann S., et al. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51:973-980.
33. Findeisen P., et al. Preanalytical impact of sample handling on proteome profiling experiments with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin. Chem. 2005, 51:2409-2411.
34. Pilny R., et al. Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artifacts in serum obtained from clot activator-containing collection devices. Clin. Chem. 2006, 52:2115-2116.
35. Rai A.J., Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev. Proteomics 2006, 3:409-426.
36. Pieragostino D., et al. Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. J. Proteomics 2010, 73:562-570.
37. Tuck M.K., et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 2009, 8:113-117.
38. Vesper H.W., Thienpont L.M. Traceability in laboratory medicine. Clin. Chem. 2009, 55:1067-1075.
39. Apweiler R., et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin. Chem. Lab. Med. 2009, 47:724-744.
40. Hamacher M., et al. Maintaining standardization: an update of the HUPO Brain Proteome Project. Expert Rev. Proteomics 2008, 5:165-173.
41. Paulovich A.G., et al. A CPTAC inter-laboratory study characterizing a yeast performance standard for benchmarking LC-MS Platform performance. Mol. Cell Proteomics 2010, 9:242-254.
42. Addona T.A., et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27:633-641.
43. Bell A.W., et al. A HUPO test sample study reveals common problems in mass spectrometry-based proteomics. Nat. Methods 2009, 6:423-430.
44. Mercier C., et al. Mixed-model of ANOVA for measurement reproducibility in proteomics. J. Proteomics 2009, 72:974-981.
45. Schulz-Trieglaff O., et al. Statistical quality assessment and outlier detection for liquid chromatography-mass spectrometry experiments. BioData Min. 2009, 2:4.
46. Kistler A.D., et al. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009, 76:89-96.
47. Cairns D.A., et al. Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics 2008, 9:519.
48. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.
49. Baggerly K.A., et al. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl. Cancer Inst. 2005, 97:307-309.
50. Karsan A., et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 2005, 51:1525-1528.
51. Wang Q., et al. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 2009, 9:287.
52. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 2007, 53:852-858.
53. Decramer S., et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat. Med. 2006, 12:398-400.
54. Haubitz M., et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol. Cell Proteomics 2009, 8:2296-2307.
55. Sherman J., et al. How specific is my SRM?: The issue of precursor and product ion redundancy. Proteomics 2009, 9:1120-1123.
56. Duncan M.W., et al. Quantifying proteins by mass spectrometry: the selectivity of SRM is only part of the problem. Proteomics 2009, 9:1124-1127.
57. Villanueva J., et al. A sequence-specific exopeptidase activity test (SSEAT) for " functional" biomarker discovery. Mol. Cell Proteomics 2008, 7:509-518.
58. Ahn Y.H., et al. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J. Proteome Res. 2009, 8:4216-4224.
59. Wollscheid B., et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat. Biotechnol. 2009, 27:378-386.
60. Anderson N.L., et al. A human proteome detection and quantitation project. Mol. Cell Proteomics 2009, 8:883-886.